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The in vitro activity of ketolide HMR 3647 against coryneform bacteria isolated from clinical samples was
evaluated. Except against Corynebacterium jeikeium and C. urealyticum, HMR 3647 showed high activity against
Corynebacterium spp., being more active than 14- and 16-membered macrolides, azithromycin, or clindamycin.
HMR 3647 also had high in vitro activity against Brevibacterium spp. and Listeria monocytogenes.
Coryneform bacteria are increasingly recognized as a cause
of human infection, particularly in hospitalized patients (6, 9).
Molecular and chemotaxonomic methods have successfully
been used in the last decade to define new genera and species
and to reclassify previously recognized coryneform bacteria,
but very few studies have been performed relative to their
medical and clinical importance. Corynebacterium urealyticum,
C. jeikeium, C. amycolatum, C. striatum, and C. minutissimum
and Brevibacterium spp. are some of the most frequently iso-
lated coryneform bacteria in clinical microbiology laboratories
(6, 9, 12). Coryneform Centers for Disease Control and Pre-
vention (CDC) groups I2 and F2 are now included in the new-
ly described species C. amycolatum (2, 4). Most of the organ-
isms previously identified as C. xerosis, some C. minutissimum
strains, and a few C. striatum strains are also currently known
to be C. amycolatum. Another clinically important gram-posi-
tive rod to be considered is Listeria monocytogenes.
C. jeikeium and C. urealyticum are commonly multi-drug re-
sistant, although strains of both species are known to be sus-
ceptible to a variety of antimicrobial agents (3, 11–14), such as
glycopeptides, and variably resistant to erythromycin, tetra-
cycline, and fluoroquinolones. Multi-drug resistance is not
found only in these two organisms; other species and groups of
coryneform bacteria (including, for example, C. amycolatum or
coryneform CDC group G) are frequently resistant to many of
the antimicrobial agents available for therapeutic use (5, 9).
Ketolide HMR 3647 is a new semisynthetic 14-membered
ring macrolide with a 3-keto group instead of the L-cladinose
sugar (1). Ketolides show the same antibacterial spectrum as
reference macrolides but also have good activity against eryth-
romycin-resistant isolates among gram-positive cocci (7). The
purpose of this study was to evaluate the in vitro activity of
the new ketolide HMR 3647 against coryneform bacteria
and L. monocytogenes isolated from human samples compared
with those of azythromycin, 14- and 16-membered macrolides,
and clindamycin.
(This work was presented at the 37th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, Toronto,
Canada, 27 September to 1 October 1997.)
The following test organisms (number of isolates) were iso-
lated from clinical samples at the Department of Clinical Mi-
crobiology, University Hospital Virgen Macarena, Seville, Spain:
C. amycolatum (35), C. jeikeium (20), C. urealyticum (20), C. stria-
tum (20), C. minutissimum (20), L. monocytogenes (15), and
Brevibacterium spp. (10). Organisms were identified by conven-
tional phenotypic tests and the API Coryne System, according
to Funke et al. (6). C. amycolatum strains included organisms
identified as C. xerosis, C. minutissimum, and CDC coryneform
group I2 by the CDC scheme for identification of coryneform
bacteria (4). After isolation and identification, bacteria were
maintained in 10% glycerol in tryptic soy broth at 270°C until
used. The following reference strains were included: C. jeikei-
um ATCC 43734, C. urealyticum ATCC 43042, and C. striatum
ATCC 6940. Staphylococcus aureus ATCC 29213 and Entero-
coccus faecalis ATCC 29212 were used as control strains.
HMR 3647 (Hoechst-Marion-Roussell, Romainville, France),
erythromycin A (Sigma, St. Louis, Mo.), clarithromycin (Ab-
bott Laboratories, Madrid, Spain), roxithromycin (Hoechst-
Marion-Roussell), josamycin (Sigma), azithromycin (Pfizer
S.A., Madrid, Spain), and clindamycin (Pharmacia-Upjohn,
Kalamazoo, Mich.) were used as powders of known potency.
Solutions of antimicrobial agents were prepared on the day of
antimicrobial testing, according to the manufacturer’s instruc-
tions.
A microdilution method was used for susceptibility testing.
The guidelines provided by the National Committee for Clin-
ical Laboratory Standards (NCCLS) for dilution susceptibility
testing (10) were followed, with some exceptions, as coryne-
form bacteria are not discussed in this document. Cation-ad-
justed Mueller-Hinton broth (Difco, Detroit, Mich.) was sup-
plemented with 0.5% Tween 80 in tests of the lypophilic
species C. jeikeium and C. urealyticum. Twofold dilutions rang-
ing from 0.03 to 64 mg/ml for all antimicrobial agents were
tested. The inoculum was prepared from bacterial cultures
grown on Columbia agar with 5% sheep blood agar for 20 to
24 h. Bacteria were suspended in Mueller-Hinton broth with
(C. jeikeium and C. urealyticum) or without 0.5% Tween 80 to
a concentration of about 108 CFU/ml and diluted in the same
medium to obtain a final concentration of 5 3 104 CFU per
well. The final volume in each well of the microtiter plate was
100 ml. Plates were inoculated and then incubated in air at
35°C for 20 to 22 h or 48 h if no growth was observed at 20 to
22 h or if the organism was C. striatum.
The MICs, MICs at which 50% of the isolates are inhibited
(MIC50s), and MIC90s of the different antimicrobial agents
evaluated are shown in Table 1. The macrolides and clinda-
mycin had low activity against Corynebacterium spp. The
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ketolide HMR 3647 showed high activity against C. amycola-
tum, C. striatum, and C. minutissimum but low activity against
the more-resistant species C. urealyticum and C. jeikeium. Sim-
ilar activities of macrolides and clindamycin against Coryne-
bacterium spp. have been reported in other studies (5, 8, 14),
although Soriano et al. (14) reported the MIC90s of erythro-
mycin for C. minutissimum strains to be several times higher
than those obtained here. It is possible that some of the
C. minutissimum strains included in the study of Soriano et
al. belong to the newly-recognized C. amycolatum species.
It is important that remarkable differences in the MICs of
ketolides and macrolides can be observed for C. striatum if
readings are made at 48 h instead of 20 h. At 48 h, all C. stria-
tum strains showed a hazy growth, lower than that observed in
control strains or in other coryneforms, in wells containing
concentrations of 32 to 64 mg/ml. Since the meaning of this
residual growth remains unclear, and C. striatum is a nonfasti-
dious bacterium, we chose to establish MICs at 20 h follow-
ing NCCLS guidelines for nonfastidious microorganisms.
This phenomenon could partially explain the higher MICs of
HMR 3647 and erythromycin for C. striatum isolates that were
obtained by other authors (15).
At a concentration of 0.5 mg/ml, which is the breakpoint of
the NCCLS for erythromycin and clindamycin, more than 90%
of C. amycolatum, C. striatum, and C. minutissimum strains
were inhibited by HMR 3647. These values decreased to 20
and 45% for C. urealyticum and C. jeikeium, respectively. At
this concentration, none of the macrolides inhibited more than
20% of Corynebacterium spp., with the exception of C. minut-
issimum. Forty to 70% of strains of the latter species were
inhibited by macrolides at 0.5 mg/ml.
The lowest MIC90s for L. monocytogenes were those of
clarithromycin (0.125 mg/ml) and those of HMR 3647 and
erythromycin (0.25 mg/ml for both antimicrobial agents). At
a concentration of 0.5 mg/ml, more than 90% of the strains
were inhibited by HMR 3647, erythromycin, clarithromycin,
and roxithromycin. Josamycin, azithromycin, and clindamycin
showed very low activity against this microorganism.
HMR 3647 was the most-active agent against Brevibacterium
spp. The MIC90 of clarithromycin (2 mg/ml) was much lower
than those of the other macrolides ($16 mg/ml).
We thank Janet Dawson for preparing the manuscript.
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Nebreda Mayoral, E. Garcı́a Sánchez, and I. Garcı́a Garcı́a. 1991. In vitro
activity of 79 antimicrobial agents against Corynebacterium group D2. Anti-
microb. Agents Chemother. 35:2140–2143.
4. Funke, G., P. A. Lawson, K. A. Bernard, and M. D. Collins. 1996. Most
Corynebacterium xerosis strains identified in the routine clinical laboratory
correspond to Corynebacterium amycolatum. J. Clin. Microbiol. 34:1124–1128.
5. Funke, G., V. Pünter, and A. Von Graevenitz. 1996. Antimicrobial suscepti-
bility patterns of some recently established coryneform bacteria. Antimicrob.
Agents Chemother. 40:2874–2878.
6. Funke, G., A. von Graevenitz, J. E. Clarridge, and K. A. Bernard. 1997.
Clinical microbiology of coryneform bacteria. Clin. Microbiol. Rev. 10:125–
159.
7. Jones, R. N., and D. J. Biedenbach. 1997. Antimicrobial activity of RU-
66647, a new ketolide. Diagn. Microbiol. Infect. Dis. 27:7–12.
8. Martı́nez-Martı́nez, L., A. Pascual, K. Bernard, and A. I. Suárez. 1996.
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